top of page
Medex EU Authorised Representative logo

Authorized Representative Duties for Legacy Devices: MDR Article 120 After Regulation (EU) 2023/607

Legacy devices still on the Union market under Article 120 of the MDR, as amended by Regulation (EU) 2023/607, still need an authorized representative when the manufacturer is outside the Union. This page explains which Article 11 tasks apply to them, how post-market surveillance and vigilance divide between manufacturer and representative, and what the representative should hold on the 26 May and 26 September 2024 conditions.

What a legacy device is, in one paragraph

A legacy device is a device still placed on the market under a certificate or declaration drawn up under the former Directives 90/385/EEC or 93/42/EEC, using the transitional regime of Article 120 of the MDR as rewritten by Regulation (EU) 2023/607. Article 120(3a) covers devices with a Directive certificate that remains valid, and Article 120(3b) covers devices that were self-declared under the Directive but need a notified body under the MDR. The dates that still apply and the conditions that have expired are set out in our note on the MDR transition period; this page looks only at what the authorized representative does for those devices.

The representative requirement applies to legacy devices too

Some manufacturers assume that a device sold under the Directive needs only what the Directive required. For the representative, that makes no practical difference, because the obligation to designate one already existed. MDCG 2021-25 Rev. 1 says so in a footnote:

"The requirement that manufacturers not established in the EU shall designate an authorised representative (Article 11(1) MDR) stems already from the AIMDD and MDD and therefore also applies to ‘legacy devices’."

Source: MDCG 2021-25 Rev. 1, footnote 7

The same footnote explains that Article 11(7) also applies, so that references to the competent authority of the manufacturer's Member State are read as references to the competent authority where the representative has its registered place of business. For a manufacturer outside the Union, that authority is the one that deals with its legacy devices.

Which MDR obligations reach the representative

Article 120(3d) is the provision that brings parts of the MDR into the legacy regime:

"By way of derogation from paragraph 3 of this Article, the requirements of this Regulation relating to post-market surveillance, market surveillance, vigilance, registration of economic operators and of devices shall apply to devices referred to in paragraphs 3a and 3b of this Article in place of the corresponding requirements in Directives 90/385/EEC and 93/42/EEC."

Source: Regulation (EU) 2017/745, Article 120(3d)

MDCG 2022-16, the guidance on authorised representatives, translates that into the representative's tasks:

"For authorised representatives, this includes Article 11(3)(c)-(g) MDR/IVDR and the mandate between the manufacturer and the authorised representative should be updated accordingly."

Source: MDCG 2022-16, Section 12

The same section states that the Directive requirements for authorised representatives continue to apply for legacy devices. In practice the representative's work for a legacy device therefore looks like this:

Article 11(3)TaskWhat it means for a legacy device
(c)RegistrationThe representative holds its own SRN under Article 31 and verifies that the manufacturer has met its registration obligations, including registration of the legacy device in EUDAMED where required
(d)Authority requestsIt provides a competent authority with the documentation showing conformity, which for a legacy device means conformity with the Directive plus the MDR requirements of Article 120(3d)
(e)Samples and accessIt forwards requests for samples or access to the manufacturer and checks that the authority receives them
(f)Corrective actionIt cooperates with the authorities on preventive or corrective action
(g)Complaints and incidentsIt informs the manufacturer immediately of complaints and suspected incident reports

Registration of legacy devices in EUDAMED, and the deadlines that now apply to it, are covered in our note on mandatory EUDAMED registration.

Post-market surveillance and vigilance

Because Article 120(3d) applies the MDR's post-market surveillance and vigilance rules, the manufacturer of a legacy device runs MDR post-market surveillance and reports serious incidents and field safety corrective actions under Article 87. MDCG 2021-25 Rev. 1 lists the manufacturer provisions that apply, including Article 10(10) and (12) to (15). The representative does not take those obligations over. Its part is the information flow of Article 11(3)(g) and the cooperation of Article 11(3)(f), and, where the mandate delegates vigilance tasks in EUDAMED, the work that delegation involves. The mandate summary registered in EUDAMED records whether the representative is mandated for vigilance. The reporting rules themselves are explained in our note on serious incident reporting and our note on post-market surveillance.

The representative's part in the May and September 2024 conditions

Article 120(3c) lets legacy devices stay on the market only if a set of conditions is met. Two of them carried 2024 deadlines, and the second names the representative directly:

"no later than 26 May 2024, the manufacturer or the authorised representative has lodged a formal application with a notified body in accordance with Section 4.3, first subparagraph, of Annex VII for conformity assessment in respect of a device referred to in paragraph 3a or 3b of this Article or in respect of a device intended to substitute that device, and, no later than 26 September 2024, the notified body and the manufacturer have signed a written agreement in accordance with Section 4.3, second subparagraph, of Annex VII."

Source: Regulation (EU) 2017/745, Article 120(3c)(e)

Three points follow from the wording. The formal application could be lodged by the representative as well as by the manufacturer. The written agreement is signed by the notified body and the manufacturer, not by the representative. And the quality management system condition in Article 120(3c)(d) is the manufacturer's alone. Both dates have passed, so for any legacy device still on the market today the conditions either were met or the device lost the benefit of the transition.

That makes evidence the practical issue for a representative. Under Article 11(3)(d) it must be able to show a competent authority that the device lawfully remains on the market, and under Article 11(3)(h) it must end the mandate if the manufacturer acts contrary to its obligations. A representative taking on, or continuing, a legacy mandate should therefore hold copies of the notified body application and the signed written agreement, together with the valid Directive certificate or the Directive declaration of conformity. Article 120(3e) also moves surveillance of the device to the notified body that signed the written agreement, so the representative should know which notified body is now responsible.

PRRC, supply interruptions and the mandate text

Two further points are easy to miss. First, the person responsible for regulatory compliance. MDCG 2022-16 states that authorised representatives whose mandate also covers legacy devices are not required to appoint a PRRC for those devices; a representative that also covers MDR devices still needs one for those under Article 15(6).

Second, Article 10a on interruption or discontinuation of supply, added by Regulation (EU) 2024/1860, applies to legacy devices as well:

"Article 10a shall also apply to devices referred to in paragraphs 3a and 3b of this Article."

Source: Regulation (EU) 2017/745, Article 120(13)

Article 10a(1) requires the manufacturer to inform the competent authority of the Member State where it or its authorised representative is established. For a manufacturer outside the Union that is the representative's authority, which is a reason to agree in the mandate how such notices are prepared and sent.

Finally, the mandate text itself. MDCG 2022-16 expects it to be updated to reflect Article 11(3)(c) to (g). Where a manufacturer changes representative for a legacy device, MDCG 2021-25 Rev. 1 also addresses the declaration of conformity:

"Where the manufacturer updates its DoC to reflect changes regarding information provided in the declaration (e.g. changes concerning the address, the authorised representative, or the validity date) the manufacturer should add a reference to the DoC which was drawn up for the legacy device before 26 May 2021."

Source: MDCG 2021-25 Rev. 1, footnote 9

The contract terms of a change are governed by Article 12 of the MDR, explained in our note on changing authorised representative and in the transfer guide.

In vitro diagnostics

This page deals with the MDR. Legacy IVDs follow Article 110 of the IVDR and its own transitional dates, and MDCG 2022-8 is the corresponding guidance. The principle for the representative is the same, as MDCG 2022-16 applies Article 11(3)(c) to (g) under both Regulations.

Frequently asked questions

Does a legacy device need an EU authorized representative?

Yes. The obligation for a manufacturer outside the Union to designate a representative existed under the Directives and continues to apply to legacy devices, as MDCG 2021-25 Rev. 1 confirms.

Which Article 11 tasks apply to legacy devices?

MDCG 2022-16 states that Article 11(3)(c) to (g) apply: registration, authority requests, samples, cooperation on corrective action and passing on complaints and incident reports. The Directive requirements for representatives also continue to apply.

Could the authorized representative lodge the 26 May 2024 application?

Yes. Article 120(3c)(e) allows the formal application to the notified body to be lodged by the manufacturer or the authorised representative. The written agreement due by 26 September 2024 is signed by the notified body and the manufacturer.

Does the representative need a PRRC for legacy devices?

According to MDCG 2022-16, a representative whose mandate covers legacy devices is not required to appoint a PRRC for those devices. Article 15(6) still applies to its MDR devices.

Related pages: MDR and IVDR transition deadline checker, EUDAMED XML generator for legacy device bulk upload, MDR Article 11.

Sources

Regulation (EU) 2017/745, consolidated text of 9 November 2026: eur-lex.europa.eu

MDCG 2021-25 Rev. 1, application of MDR requirements to legacy devices (October 2024): health.ec.europa.eu

MDCG 2022-16, Guidance on Authorised Representatives (October 2022): health.ec.europa.eu

Regulation (EU) 2023/607: eur-lex.europa.eu

Request a fixed-price EU authorized representative quote for your legacy and MDR devices under one mandate.

Request a proposal  ·  View pricing  ·  Our EU REP service

bottom of page